Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2025
0mins
Source: Newsfilter
Merger Announcement: Kronos Bio, Inc. has entered into a definitive merger agreement with Concentra Biosciences, LLC, where Concentra will acquire Kronos Bio for $0.57 per share in cash plus contingent value rights related to future product sales and cost savings.
Shareholder Support and Conditions: The acquisition has been approved by Kronos Bio's Board of Directors and is supported by shareholders holding approximately 27% of the company's stock; the tender offer is expected to commence by May 15, 2025, subject to certain conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
